首页 > 最新文献

Acta Pharmaceutica Sinica. B最新文献

英文 中文
Complete biosynthesis of phenylspirodrimanes with unclustered genes in Stachybotrys chartarum 带非聚类基因的苯螺旋烷的完全生物合成。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-09-13 DOI: 10.1016/j.apsb.2025.09.015
Jimei Liu, Ridao Chen, Min Zhang, Yangyang Duan, Keping Feng, Songyang Sui, Yaotian Han, Kebo Xie, Jun Wu, Haibo Yu, Dawei Chen, Jungui Dai
Phenylspirodrimanes are a class of structurally diverse meroterpenoids, including the bioactive dimer stachybocin A (1) and the high-reactivity monomer stachybotrydial (2), which are isolated from the genus Stachybotrys. Whereas the biosynthetic pathway of these phenylspirodrimane meroterpenoids has remained elusive. Herein, we deciphered the complete biosynthetic pathway of 2 with unprecedented two gene clusters and five discrete genes by genome mining, gene inactivation, heterologous expression, biochemical experiments, and especially combining with transcriptome-based hierarchical clustering and expression correlation analyses. Totally, 11 genes for the phenylspirodrimane core skeleton formation, 8′-methyl oxidation, and 3-OH epimerization were efficiently discovered and functionally characterized. Notably, these biosynthetic genes are distributed across seven distinct regions, with a rare combination of multiple gene clusters and genes outside the clusters. Bioactivity assays revealed that four intermediates 68, and 9a exhibited significant inhibitory effect on the inactivated state hNaV1.2 channels with IC50 values of 0.15, 0.04, 0.28, and 1.91 μmol/L, respectively. These findings expand our understanding of phenylspirodrimane-type meroterpenoid biosynthesis and underscore the utility of transcriptome-based hierarchical clustering and expression correlation analyses for identifying unclustered biosynthetic genes in fungi.
Phenylspirodrimanes是一类结构多样的巯基萜类化合物,包括生物活性二聚体stachybocin a(1)和高反应性单体stachybotrydial(2),它们是从Stachybotrys属中分离出来的。然而,这些苯基螺旋体萜类化合物的生物合成途径仍然是难以捉摸的。本文通过基因组挖掘、基因失活、异源表达、生化实验,特别是结合基于转录组的分层聚类和表达相关性分析,史无前例地破译了2的2个基因簇和5个离散基因的完整生物合成途径。共发现了11个与苯螺烷核心骨架形成、8′-甲基氧化和3-OH外映异构化有关的基因,并对其进行了功能表征。值得注意的是,这些生物合成基因分布在七个不同的区域,具有罕见的多基因簇和簇外基因的组合。生物活性测定表明,4个中间体6-8和9a对hNaV1.2失活状态通道具有显著的抑制作用,IC50值分别为0.15、0.04、0.28和1.91 μmol/L。这些发现扩大了我们对苯螺烷型美罗萜类生物合成的理解,并强调了基于转录组的分层聚类和表达相关性分析在鉴定真菌非聚类生物合成基因方面的实用性。
{"title":"Complete biosynthesis of phenylspirodrimanes with unclustered genes in Stachybotrys chartarum","authors":"Jimei Liu,&nbsp;Ridao Chen,&nbsp;Min Zhang,&nbsp;Yangyang Duan,&nbsp;Keping Feng,&nbsp;Songyang Sui,&nbsp;Yaotian Han,&nbsp;Kebo Xie,&nbsp;Jun Wu,&nbsp;Haibo Yu,&nbsp;Dawei Chen,&nbsp;Jungui Dai","doi":"10.1016/j.apsb.2025.09.015","DOIUrl":"10.1016/j.apsb.2025.09.015","url":null,"abstract":"<div><div>Phenylspirodrimanes are a class of structurally diverse meroterpenoids, including the bioactive dimer stachybocin A (<strong>1</strong>) and the high-reactivity monomer stachybotrydial (<strong>2</strong>), which are isolated from the genus <em>Stachybotrys</em>. Whereas the biosynthetic pathway of these phenylspirodrimane meroterpenoids has remained elusive. Herein, we deciphered the complete biosynthetic pathway of <strong>2</strong> with unprecedented two gene clusters and five discrete genes by genome mining, gene inactivation, heterologous expression, biochemical experiments, and especially combining with transcriptome-based hierarchical clustering and expression correlation analyses. Totally, 11 genes for the phenylspirodrimane core skeleton formation, 8′-methyl oxidation, and 3-OH epimerization were efficiently discovered and functionally characterized. Notably, these biosynthetic genes are distributed across seven distinct regions, with a rare combination of multiple gene clusters and genes outside the clusters. Bioactivity assays revealed that four intermediates <strong>6</strong>−<strong>8</strong>, and <strong>9a</strong> exhibited significant inhibitory effect on the inactivated state hNa<sub>V</sub>1.2 channels with IC<sub>50</sub> values of 0.15, 0.04, 0.28, and 1.91 μmol/L, respectively. These findings expand our understanding of phenylspirodrimane-type meroterpenoid biosynthesis and underscore the utility of transcriptome-based hierarchical clustering and expression correlation analyses for identifying unclustered biosynthetic genes in fungi.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 966-978"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
REEP6 promotes colorectal cancer glycolysis and tumorigenesis through PRMT5-mediated PGAM1 arginine methylation REEP6通过prmt5介导的PGAM1精氨酸甲基化促进结直肠癌糖酵解和肿瘤发生。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-10-24 DOI: 10.1016/j.apsb.2025.10.025
Tuo Wang , Dongsheng Zhang , Chi Jin , Hengjie Xu , Hongxu Nie , Ye Wang , Chuan Zhang , Yifei Feng , Junwei Tang , Yueming Sun
Metabolic reprogramming is a notable hallmark of cancer biology, especially aerobic glycolysis. Some clinical trials attempt to target cancer metabolism to develop therapeutic agents. However, the results have been not satisfactory. Here, we report that REEP6 is significantly upregulated and promotes glycolysis and tumorigenesis in CRC. Moreover, REEP6, as a molecular scaffolder, bridges the PRMT5–PGAM1 complex, which enhances the PRMT5-mediated symmetric dimethylarginine (SDMA) of PGAM1 at R40. The methylated PGAM1 possesses dramatically enhanced enzymatic activity and therefore boosts glycolytic flux in CRC cells. More than that, our results showed that combined treatment with specific shRNA and inhibitors exhibits synergistic anti-tumor efficacy in CRC, which may shed light on the development of a promising therapy in CRC.
代谢重编程是癌症生物学的一个显著标志,尤其是有氧糖酵解。一些临床试验试图以癌症代谢为目标来开发治疗药物。然而,结果并不令人满意。在这里,我们报道REEP6在结直肠癌中显著上调并促进糖酵解和肿瘤发生。此外,REEP6作为分子支架,桥接PRMT5-PGAM1复合物,增强了prmt5介导的PGAM1对称二甲基精氨酸(SDMA)在R40位点的表达。甲基化的PGAM1具有显著增强的酶活性,因此促进CRC细胞的糖酵解通量。更重要的是,我们的研究结果表明,特异性shRNA和抑制剂联合治疗在结直肠癌中具有协同抗肿瘤功效,这可能为开发一种有前景的结直肠癌治疗方法提供了线索。
{"title":"REEP6 promotes colorectal cancer glycolysis and tumorigenesis through PRMT5-mediated PGAM1 arginine methylation","authors":"Tuo Wang ,&nbsp;Dongsheng Zhang ,&nbsp;Chi Jin ,&nbsp;Hengjie Xu ,&nbsp;Hongxu Nie ,&nbsp;Ye Wang ,&nbsp;Chuan Zhang ,&nbsp;Yifei Feng ,&nbsp;Junwei Tang ,&nbsp;Yueming Sun","doi":"10.1016/j.apsb.2025.10.025","DOIUrl":"10.1016/j.apsb.2025.10.025","url":null,"abstract":"<div><div>Metabolic reprogramming is a notable hallmark of cancer biology, especially aerobic glycolysis. Some clinical trials attempt to target cancer metabolism to develop therapeutic agents. However, the results have been not satisfactory. Here, we report that REEP6 is significantly upregulated and promotes glycolysis and tumorigenesis in CRC. Moreover, REEP6, as a molecular scaffolder, bridges the PRMT5–PGAM1 complex, which enhances the PRMT5-mediated symmetric dimethylarginine (SDMA) of PGAM1 at R40. The methylated PGAM1 possesses dramatically enhanced enzymatic activity and therefore boosts glycolytic flux in CRC cells. More than that, our results showed that combined treatment with specific shRNA and inhibitors exhibits synergistic anti-tumor efficacy in CRC, which may shed light on the development of a promising therapy in CRC.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 948-965"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author correction to “Cerium single-atom catalysts-armed Lactobacillus reuteri for multipronged anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease” [Acta Pharmaceutica Sinica B 15 (2025) 5400-5415] 勘误:作者更正“铈单原子催化剂武装罗伊氏乳杆菌用于炎症性肠病的多管齐下抗炎/抗纤维化治疗”[药物学报B 15(2025) 5400-5415]。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-01 DOI: 10.1016/j.apsb.2025.12.001
Yinying Pu , Shaorong Huang , Shuang Gao , Yangying Duan , Wenhao Li , Qiyue Li , Han Lin , Kun Zhang , Min Zhou , Wencheng Wu
{"title":"Author correction to “Cerium single-atom catalysts-armed Lactobacillus reuteri for multipronged anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease” [Acta Pharmaceutica Sinica B 15 (2025) 5400-5415]","authors":"Yinying Pu ,&nbsp;Shaorong Huang ,&nbsp;Shuang Gao ,&nbsp;Yangying Duan ,&nbsp;Wenhao Li ,&nbsp;Qiyue Li ,&nbsp;Han Lin ,&nbsp;Kun Zhang ,&nbsp;Min Zhou ,&nbsp;Wencheng Wu","doi":"10.1016/j.apsb.2025.12.001","DOIUrl":"10.1016/j.apsb.2025.12.001","url":null,"abstract":"","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1173-1174"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An immunostimulant nanomedicine enhances radioimmunotherapy by remodeling the tumor immunosuppressive landscape after radiotherapy 一种免疫刺激纳米药物通过重塑放射治疗后的肿瘤免疫抑制景观来增强放射免疫治疗。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-11-13 DOI: 10.1016/j.apsb.2025.11.012
Mengwan Jiang , Mingyue Chen , Wen Zou , Yingxin Xie , Jinjin Shi , Junjie Liu , Aibing Chen , Xiu Zhao
Studies have shown that radiotherapy (RT) has powerful immune-stimulating effects. However, RT-mediated distal tumor regression is rare in clinical practice. Here, with an animal experimental model, we found that RT shaped an immunosuppressive landscape characterized by a high-influx of myeloid-derived suppressor cells (MDSCs), and the induction of immunologically silent tumor apoptosis, hindering the efficacy of radioimmunotherapy. To address this issue, we developed a spatiotemporally controlled nanomedicine for remodeling the immunosuppressive tumor microenvironment (TME) post-RT. Decitabine (DAC)-loaded ferritin (Ft) were crosslinked via an azobenzene linker, and meanwhile encapsulated with all-trans retinoic acid (ATRA) to construct a Ft@DAC@ATRA nanoassembly (denoted as FD@ATRA), which dissociated into monodispersive Ft@DAC units in hypoxia TME. The released ATRA could eliminate immunosuppressive MDSCs, and meanwhile Ft@DAC selectively induced immunogenic pyroptosis of the tumor by targeting the transferrin receptor 1 overexpressed on the tumor to effectively activate CD8+ T cells. FD@ATRA treatment reshaped the tumor immune landscape post-RT with an increase of 16.8% in tumor-infiltrating IFN-γ+CD8+ T cells. Moreover, FD@ATRA-enhanced RT remained effective in large, treatment-resistant tumors, and the inhibition rate of FD@ATRA-enhanced RT on distant tumors improved by 47% compared to the RT group alone, providing an effective therapeutic approach to improve the clinical outcomes of radioimmunotherapy.
研究表明放射治疗(RT)具有强大的免疫刺激作用。然而,在临床实践中,rt介导的远端肿瘤消退是罕见的。在这里,通过动物实验模型,我们发现RT形成了一种免疫抑制景观,其特征是髓源性抑制细胞(MDSCs)大量涌入,并诱导免疫沉默的肿瘤凋亡,阻碍了放射免疫治疗的疗效。为了解决这一问题,我们开发了一种时空控制的纳米药物,用于重建rt后的免疫抑制肿瘤微环境(TME)。负载地西他滨(DAC)的铁蛋白(Ft)通过偶氮苯连接剂交联,同时与全反式维甲酸(ATRA)包裹,构建Ft@DAC@ATRA纳米组装体(表示为FD@ATRA),该纳米组装体在缺氧TME中解离成单分散的Ft@DAC单元。释放的ATRA可以清除免疫抑制的MDSCs,同时Ft@DAC选择性诱导肿瘤免疫原性焦凋亡,通过靶向肿瘤上过表达的转铁蛋白受体1,有效激活CD8+ T细胞。FD@ATRA治疗重塑了rt后的肿瘤免疫景观,肿瘤浸润的IFN-γ +CD8+ T细胞增加16.8%。此外,FD@ATRA-enhanced RT对大的、治疗耐药的肿瘤仍然有效,与单独RT组相比,FD@ATRA-enhanced RT对远处肿瘤的抑制率提高了47%,为改善放射免疫治疗的临床结果提供了一种有效的治疗方法。
{"title":"An immunostimulant nanomedicine enhances radioimmunotherapy by remodeling the tumor immunosuppressive landscape after radiotherapy","authors":"Mengwan Jiang ,&nbsp;Mingyue Chen ,&nbsp;Wen Zou ,&nbsp;Yingxin Xie ,&nbsp;Jinjin Shi ,&nbsp;Junjie Liu ,&nbsp;Aibing Chen ,&nbsp;Xiu Zhao","doi":"10.1016/j.apsb.2025.11.012","DOIUrl":"10.1016/j.apsb.2025.11.012","url":null,"abstract":"<div><div>Studies have shown that radiotherapy (RT) has powerful immune-stimulating effects. However, RT-mediated distal tumor regression is rare in clinical practice. Here, with an animal experimental model, we found that RT shaped an immunosuppressive landscape characterized by a high-influx of myeloid-derived suppressor cells (MDSCs), and the induction of immunologically silent tumor apoptosis, hindering the efficacy of radioimmunotherapy. To address this issue, we developed a spatiotemporally controlled nanomedicine for remodeling the immunosuppressive tumor microenvironment (TME) post-RT. Decitabine (DAC)-loaded ferritin (Ft) were crosslinked <em>via</em> an azobenzene linker, and meanwhile encapsulated with all-trans retinoic acid (ATRA) to construct a Ft@DAC@ATRA nanoassembly (denoted as FD@ATRA), which dissociated into monodispersive Ft@DAC units in hypoxia TME. The released ATRA could eliminate immunosuppressive MDSCs, and meanwhile Ft@DAC selectively induced immunogenic pyroptosis of the tumor by targeting the transferrin receptor 1 overexpressed on the tumor to effectively activate CD8<sup>+</sup> T cells. FD@ATRA treatment reshaped the tumor immune landscape post-RT with an increase of 16.8% in tumor-infiltrating IFN-<em>γ</em><sup>+</sup>CD8<sup>+</sup> T cells. Moreover, FD@ATRA-enhanced RT remained effective in large, treatment-resistant tumors, and the inhibition rate of FD@ATRA-enhanced RT on distant tumors improved by 47% compared to the RT group alone, providing an effective therapeutic approach to improve the clinical outcomes of radioimmunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1059-1073"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systemic immunogenic reactor leveraging modified γ-cyclodextrins for photo-controlled cancer Ca2+ interference via modulating MICU1 利用修饰的γ-环糊精通过调节MICU1光控癌症Ca2+干扰的全身免疫原反应器。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-11-03 DOI: 10.1016/j.apsb.2025.10.046
Qian Jing , Mengnan Zhao , Yan Tang, Tao Chen, Mingyan Sun, Dandan Mi, Lan Zou, Rujing Wang, Jun Lu, Sanjun Shi
Interference with calcium homeostasis provokes tumor cell death and immune response, providing a novel direction for tumor immunotherapy as a promising cancer treatment strategy. Nevertheless, most reported Ca2+-overloaded nanoinducers encounter challenges such as intricate preparation procedures, safety concerns arising from inorganic material input, and limited anti-tumor efficiency. Herein, we synthesized a biocompatible and pH-sensitive Ca-doped cyclodextrin metal-organic framework (Ca/K-MOF) as a carrier, which was then loaded with photosensitizer hypericin (HY) via a simple one-pot synthesis to form HY@Ca/K-MOF. To enhance the stability both in vitro and in vivo, we coated HY@Ca/K-MOF with a hydrophilic layer of PEG (PEGHY@Ca/K-MOF). When exposed to 590 nm photoirradiation, PEGHY@Ca/K-MOF, with its pH-responsive dissociation, the Ca2+ and HY mediators released at the tumor site share the responsibility of triggering intracellular Ca2+ disturbances, which amplified the production of reactive oxygen species (ROS) and led to mitochondrial calcium overload through modulating mitochondrial MICU1 function. Under photocontrol, this interplay between ROS generation and mitochondrial calcium overload created a bidirectional amplification effect, where each process reinforced the other, subsequently eliciting a pyroptosis-evoked immune response. Significantly, this newly constructed delivery platform effectively suppressed both primary and distant tumors without the need for additional immunological interventions. In summary, this Ca2+-doped MOF-based nanomaterial provides a promising approach for efficient tumor photo-controlled mitochondrial Ca2+ overload-pyroptosis immunotherapy.
干扰钙稳态引起肿瘤细胞死亡和免疫应答,为肿瘤免疫治疗提供了新的方向,是一种很有前景的癌症治疗策略。然而,大多数报道的Ca2+超载纳米诱导剂遇到了诸如复杂的制备程序、无机材料输入引起的安全问题和有限的抗肿瘤效率等挑战。本研究合成了一种具有生物相容性和ph敏感性的掺钙环糊精金属有机骨架(Ca/K-MOF)作为载体,然后通过简单的一锅合成法将光敏剂金丝桃素(HY)负载在环糊精金属有机骨架上,形成HY@Ca/K-MOF。为了提高体外和体内的稳定性,我们在HY@Ca/K-MOF上包裹了一层亲水的PEG (PEGHY@Ca/K-MOF)。当暴露于590nm光照射时,PEGHY@Ca/K-MOF,其ph响应解离,在肿瘤部位释放的Ca2+和HY介质共同触发细胞内Ca2+干扰,从而放大活性氧(ROS)的产生,并通过调节线粒体MICU1功能导致线粒体钙超载。在光控制下,ROS生成和线粒体钙超载之间的相互作用产生了双向放大效应,其中每个过程都加强了另一个过程,随后引发了焦热诱发的免疫反应。值得注意的是,这个新构建的给药平台有效地抑制了原发性和远处肿瘤,而不需要额外的免疫干预。总之,这种Ca2+掺杂mof基纳米材料为有效的肿瘤光控线粒体Ca2+超载焦亡免疫治疗提供了一种有希望的方法。
{"title":"A systemic immunogenic reactor leveraging modified γ-cyclodextrins for photo-controlled cancer Ca2+ interference via modulating MICU1","authors":"Qian Jing ,&nbsp;Mengnan Zhao ,&nbsp;Yan Tang,&nbsp;Tao Chen,&nbsp;Mingyan Sun,&nbsp;Dandan Mi,&nbsp;Lan Zou,&nbsp;Rujing Wang,&nbsp;Jun Lu,&nbsp;Sanjun Shi","doi":"10.1016/j.apsb.2025.10.046","DOIUrl":"10.1016/j.apsb.2025.10.046","url":null,"abstract":"<div><div>Interference with calcium homeostasis provokes tumor cell death and immune response, providing a novel direction for tumor immunotherapy as a promising cancer treatment strategy. Nevertheless, most reported Ca<sup>2+</sup>-overloaded nanoinducers encounter challenges such as intricate preparation procedures, safety concerns arising from inorganic material input, and limited anti-tumor efficiency. Herein, we synthesized a biocompatible and pH-sensitive Ca-doped cyclodextrin metal-organic framework (Ca/K-MOF) as a carrier, which was then loaded with photosensitizer hypericin (HY) <em>via</em> a simple one-pot synthesis to form HY@Ca/K-MOF. To enhance the stability both <em>in vitro</em> and <em>in vivo</em>, we coated HY@Ca/K-MOF with a hydrophilic layer of PEG (<sup>PEG</sup>HY@Ca/K-MOF). When exposed to 590 nm photoirradiation, <sup>PEG</sup>HY@Ca/K-MOF, with its pH-responsive dissociation, the Ca<sup>2+</sup> and HY mediators released at the tumor site share the responsibility of triggering intracellular Ca<sup>2+</sup> disturbances, which amplified the production of reactive oxygen species (ROS) and led to mitochondrial calcium overload through modulating mitochondrial MICU1 function. Under photocontrol, this interplay between ROS generation and mitochondrial calcium overload created a bidirectional amplification effect, where each process reinforced the other, subsequently eliciting a pyroptosis-evoked immune response. Significantly, this newly constructed delivery platform effectively suppressed both primary and distant tumors without the need for additional immunological interventions. In summary, this Ca<sup>2+</sup>-doped MOF-based nanomaterial provides a promising approach for efficient tumor photo-controlled mitochondrial Ca<sup>2+</sup> overload-pyroptosis immunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1116-1139"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma 酪氨酸激酶抑制剂的氘修饰有助于通过上调肝细胞癌中的醛氧化酶1来逆转铁中毒耐药性。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-06 DOI: 10.1016/j.apsb.2025.12.007
Yue Ma , Chenhe Yi , Ning Cai , Baorui Tao , Yan Geng , Weiqing Shao , Rongquan Sun , Zhenmei Chen , Yitong Li , Bo Zhang , Xiangyu Wang , Jing Lin , Wenwei Zhu , Lu Lu , Wanguang Zhang , Jinhong Chen
The susceptibility to ferroptosis partially determines the efficacy of tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC), exposing a mechanistic vulnerability that can be therapeutically exploited. The development of deuterated compounds is a promising strategy for the improvement of anti-tumor efficacy. Here, we identified HCC with higher level of ferroptosis-resistance exhibited insensitive to TKIs, which could be reversed by deuterated TKIs. Aldehyde oxidase 1 (AOX1) was screened as a critical gene mediating the responsiveness to deuterated TKIs-induced ferroptosis in HCC. The presence of a pyridyl tri-deuterated methanamide contributed to the upregulation of AOX1 in a structure-dependent manner, thereby promoting ferroptosis. Mechanistically, AOX1 inhibited sirtuin 6-mediated deacetylation of H3K9 and H3K56, leading to transcriptional activation of acyl-CoA synthetase long chain family member 5, which resulted in poly-unsaturated fatty acids hyperaccumulation-induced ferroptosis. Additionally, HCC with lower AOX1 expression conferred better efficacy to deuterated TKIs. In patient cohorts with HCC, those with lower AOX1 expression exhibited a more pronounced therapeutic response to deuterated sorafenib. Overall, the present study elucidates the mechanism by which deuterated TKIs reverse TKI resistance by promoting ferroptosis and suggests that AOX1 could serve as a biomarker to guide clinical decision-making for deuterated TKI treatment in HCC.
对铁下垂的易感性部分决定了酪氨酸激酶抑制剂(TKIs)在肝细胞癌(HCC)中的疗效,揭示了一种可用于治疗的机制脆弱性。氘化化合物的开发是提高抗肿瘤疗效的一种很有前途的策略。在这里,我们发现具有较高水平的铁致凋亡抗性的HCC对TKIs不敏感,这可以通过氘化TKIs逆转。醛氧化酶1 (AOX1)被筛选为介导HCC对氘化tkis诱导的铁下沉的关键基因。吡啶基三氘化甲酰胺的存在以结构依赖的方式促进AOX1的上调,从而促进铁死亡。机制上,AOX1抑制sirtuin 6介导的H3K9和H3K56的去乙酰化,导致酰基辅酶a合成酶长链家族成员5的转录激活,导致多不饱和脂肪酸高蓄积诱导的铁凋亡。此外,AOX1表达较低的HCC对氘化TKIs有更好的疗效。在HCC患者队列中,AOX1表达较低的患者对贫化索拉非尼表现出更明显的治疗反应。总体而言,本研究阐明了氘化TKI通过促进铁下沉逆转TKI耐药的机制,并提示AOX1可作为指导HCC中氘化TKI治疗临床决策的生物标志物。
{"title":"Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma","authors":"Yue Ma ,&nbsp;Chenhe Yi ,&nbsp;Ning Cai ,&nbsp;Baorui Tao ,&nbsp;Yan Geng ,&nbsp;Weiqing Shao ,&nbsp;Rongquan Sun ,&nbsp;Zhenmei Chen ,&nbsp;Yitong Li ,&nbsp;Bo Zhang ,&nbsp;Xiangyu Wang ,&nbsp;Jing Lin ,&nbsp;Wenwei Zhu ,&nbsp;Lu Lu ,&nbsp;Wanguang Zhang ,&nbsp;Jinhong Chen","doi":"10.1016/j.apsb.2025.12.007","DOIUrl":"10.1016/j.apsb.2025.12.007","url":null,"abstract":"<div><div>The susceptibility to ferroptosis partially determines the efficacy of tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC), exposing a mechanistic vulnerability that can be therapeutically exploited. The development of deuterated compounds is a promising strategy for the improvement of anti-tumor efficacy. Here, we identified HCC with higher level of ferroptosis-resistance exhibited insensitive to TKIs, which could be reversed by deuterated TKIs. Aldehyde oxidase 1 (AOX1) was screened as a critical gene mediating the responsiveness to deuterated TKIs-induced ferroptosis in HCC. The presence of a pyridyl tri-deuterated methanamide contributed to the upregulation of AOX1 in a structure-dependent manner, thereby promoting ferroptosis. Mechanistically, AOX1 inhibited sirtuin 6-mediated deacetylation of H3K9 and H3K56, leading to transcriptional activation of acyl-CoA synthetase long chain family member 5, which resulted in poly-unsaturated fatty acids hyperaccumulation-induced ferroptosis. Additionally, HCC with lower AOX1 expression conferred better efficacy to deuterated TKIs. In patient cohorts with HCC, those with lower AOX1 expression exhibited a more pronounced therapeutic response to deuterated sorafenib. Overall, the present study elucidates the mechanism by which deuterated TKIs reverse TKI resistance by promoting ferroptosis and suggests that AOX1 could serve as a biomarker to guide clinical decision-making for deuterated TKI treatment in HCC.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 802-819"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid in vivo release of paclitaxel from polymeric micelles 紫杉醇在聚合物胶束中的体内快速释放。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-03 DOI: 10.1016/j.apsb.2025.11.034
Haisheng He , Jianping Qi , Yi Lu , Wei Wu
Profiling in vivo release kinetics of drug nanocarriers is of high translational significance. However, this has remained unrealized due to the lack of direct methodologies to quantify either the total released or residual drugs. This study employed an indirect strategy, comparing pharmacokinetics and particokinetics, to estimate the in vivo release kinetics of paclitaxel (PTX) from intravenously administered mPEG-PDLLA polymeric micelles (PMs). Blood pharmacokinetics were profiled by chromatographically quantifying PTX, while particokinetics were determined following labeling PM particles by near-infrared fluorophores with aggregation-caused quenching properties. By monitoring the dynamic change in the PTX-to-copolymer ratio, the in vivo release of PTX from the PMs was estimated. The results revealed surprisingly rapid release, with over 88.2% and 99.0% of PTX released by 15 s and 5 min post-administration, respectively. It is concluded that PTX is released rapidly from PMs in vivo, and PMs may merely work as “solvents” to solubilize PTX rather than as carriers for targeted delivery.
分析药物纳米载体的体内释放动力学具有很高的翻译意义。然而,由于缺乏直接的方法来量化释放的总药物或残留药物,这一点仍未实现。本研究采用间接策略,比较药代动力学和颗粒动力学,以估计紫杉醇(PTX)从静脉注射的mPEG-PDLLA聚合物胶束(pm)中的体内释放动力学。血液药代动力学通过色谱定量分析PTX,而颗粒动力学通过近红外荧光团标记PM颗粒(具有聚集引起的猝灭特性)来确定。通过监测PTX与共聚物比例的动态变化,估计PMs中PTX的体内释放量。结果显示令人惊讶的快速释放,在给药后15 s和5 min分别有超过88.2%和99.0%的PTX释放。由此可见,PTX在体内从pmms中快速释放,pmms可能仅作为溶解PTX的“溶剂”,而不是作为靶向递送的载体。
{"title":"Rapid in vivo release of paclitaxel from polymeric micelles","authors":"Haisheng He ,&nbsp;Jianping Qi ,&nbsp;Yi Lu ,&nbsp;Wei Wu","doi":"10.1016/j.apsb.2025.11.034","DOIUrl":"10.1016/j.apsb.2025.11.034","url":null,"abstract":"<div><div>Profiling <em>in vivo</em> release kinetics of drug nanocarriers is of high translational significance. However, this has remained unrealized due to the lack of direct methodologies to quantify either the total released or residual drugs. This study employed an indirect strategy, comparing pharmacokinetics and particokinetics, to estimate the <em>in vivo</em> release kinetics of paclitaxel (PTX) from intravenously administered mPEG-PDLLA polymeric micelles (PMs). Blood pharmacokinetics were profiled by chromatographically quantifying PTX, while particokinetics were determined following labeling PM particles by near-infrared fluorophores with aggregation-caused quenching properties. By monitoring the dynamic change in the PTX-to-copolymer ratio, the <em>in vivo</em> release of PTX from the PMs was estimated. The results revealed surprisingly rapid release, with over 88.2% and 99.0% of PTX released by 15 s and 5 min post-administration, respectively. It is concluded that PTX is released rapidly from PMs <em>in vivo</em>, and PMs may merely work as “solvents” to solubilize PTX rather than as carriers for targeted delivery.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1155-1165"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing deep learning to accelerate the development of antibodies and aptamers 利用深度学习加速抗体和适配体的开发。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.apsb.2025.12.017
Pan Tan , Song Li , Jin Huang , Ziyi Zhou , Liang Hong
Artificial intelligence (AI) has revolutionized the design of antibodies and RNA aptamers, driving significant advancements in molecular therapeutics. In antibody design, AI enables accurate structure prediction and optimization of binding affinity, specificity, and stability, thereby accelerating the development of therapies targeting challenging antigens, such as those associated with viral infections and cancer. By integrating sequence and structural data, AI significantly reduces experimental costs and development timelines, streamlining the creation of next-generation antibody-based therapeutics. Similarly, AI has transformed RNA aptamer design, addressing long-standing challenges in structure prediction and binding optimization. AI-driven approaches allow for the rapid generation of aptamers with enhanced specificity, stability, and functional properties, expanding their potential applications in both therapeutics and diagnostics. These advancements offer scalable, cost-effective, and highly customizable solutions for precision medicine. As AI systems continue to evolve and integrate with experimental validation, they hold immense promise for developing more effective treatments for complex diseases, including cancer, autoimmune disorders, and viral infections. This marks the beginning of a new era in therapeutic innovation, where AI plays a pivotal role in addressing the challenges of modern medicine.
人工智能(AI)彻底改变了抗体和RNA适配体的设计,推动了分子治疗的重大进步。在抗体设计中,人工智能能够准确预测结构并优化结合亲和力、特异性和稳定性,从而加速针对挑战性抗原(例如与病毒感染和癌症相关的抗原)的治疗方法的开发。通过整合序列和结构数据,人工智能大大降低了实验成本和开发时间,简化了下一代基于抗体的治疗方法的创建。同样,人工智能也改变了RNA适体设计,解决了结构预测和结合优化方面长期存在的挑战。人工智能驱动的方法允许快速生成具有增强特异性、稳定性和功能特性的适配体,扩大其在治疗和诊断方面的潜在应用。这些进步为精准医疗提供了可扩展、具有成本效益和高度可定制的解决方案。随着人工智能系统的不断发展,并与实验验证相结合,它们为开发更有效的治疗复杂疾病(包括癌症、自身免疫性疾病和病毒感染)带来了巨大的希望。这标志着治疗创新新时代的开始,人工智能在应对现代医学挑战方面发挥着关键作用。
{"title":"Harnessing deep learning to accelerate the development of antibodies and aptamers","authors":"Pan Tan ,&nbsp;Song Li ,&nbsp;Jin Huang ,&nbsp;Ziyi Zhou ,&nbsp;Liang Hong","doi":"10.1016/j.apsb.2025.12.017","DOIUrl":"10.1016/j.apsb.2025.12.017","url":null,"abstract":"<div><div>Artificial intelligence (AI) has revolutionized the design of antibodies and RNA aptamers, driving significant advancements in molecular therapeutics. In antibody design, AI enables accurate structure prediction and optimization of binding affinity, specificity, and stability, thereby accelerating the development of therapies targeting challenging antigens, such as those associated with viral infections and cancer. By integrating sequence and structural data, AI significantly reduces experimental costs and development timelines, streamlining the creation of next-generation antibody-based therapeutics. Similarly, AI has transformed RNA aptamer design, addressing long-standing challenges in structure prediction and binding optimization. AI-driven approaches allow for the rapid generation of aptamers with enhanced specificity, stability, and functional properties, expanding their potential applications in both therapeutics and diagnostics. These advancements offer scalable, cost-effective, and highly customizable solutions for precision medicine. As AI systems continue to evolve and integrate with experimental validation, they hold immense promise for developing more effective treatments for complex diseases, including cancer, autoimmune disorders, and viral infections. This marks the beginning of a new era in therapeutic innovation, where AI plays a pivotal role in addressing the challenges of modern medicine.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 788-801"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut microbiota drives the metabolic dysregulation in obesity-prone individuals by impairing GDCA-mediated activation of brown adipose thermogenesis and ileal GLP-1 secretion 肠道微生物群通过损害gdca介导的棕色脂肪产热激活和回肠GLP-1分泌,驱动肥胖易感个体的代谢失调。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-07 DOI: 10.1016/j.apsb.2025.12.006
Han Ma , Yuqi Wu , Delong Li , Haowen Sun , Yuan Xie , Shichun Zhao , Wenqian Guo , Meng Wang , Renyun Cui , Yanrong Huang , Xiankang Zhang , Jin-Yi Wan , Haiqiang Yao , Chun-Su Yuan
Obesity-prone (OP) individuals exhibit an intrinsic predisposition to obesity and associated metabolic disorders, and early intervention in this population holds significant clinical value; however, the underlying mechanisms driving this susceptibility remain largely obscure. This study enrolled 46 OP subjects without diagnosed metabolic diseases and 35 healthy controls. Our findings revealed that, despite not reaching obesity diagnoses, OP subjects exhibited significant metabolic disturbances strongly associated with gut microbiota dysbiosis. They also displayed disturbed bile acid (BA) profiles, with depleted glycodeoxycholic acid (GDCA) identified as the most potent discriminator between the OP and healthy controls. Fecal microbiota transplantation (FMT) recapitulated metabolic dysfunction and BA pool remodeling, mediated by dysregulated hepatic expression of BA synthesis genes of Cyp8a1, Cyp7a1, and Cyp7b1. Notably, FMT-OP mice also phenocopied the diminished GDCA levels observed in OP subjects. GDCA supplementation in obese mice markedly improved body weight, hepatic steatosis, and metabolic dysfunction. Mechanistically, GDCA exerted anti-obesity effects by activating the TGR5 signaling, which enhanced brown adipose tissue (BAT) thermogenesis and stimulated ileal glucagon-like peptide-1 (GLP-1) secretion, thereby ameliorating obesity and associated metabolic dysregulation. Thus, these findings indicate that gut microbiota-driven dysregulation of BA signaling, particularly impaired TGR5 activation due to diminished GDCA, underlies glycolipid metabolic dysfunction in OP individuals.
肥胖易感性(OP)个体表现出肥胖和相关代谢紊乱的内在易感性,对这一人群的早期干预具有重要的临床价值;然而,驱动这种易感性的潜在机制在很大程度上仍然不清楚。本研究招募了46名未诊断出代谢疾病的OP受试者和35名健康对照者。我们的研究结果显示,尽管没有达到肥胖诊断,OP受试者表现出与肠道微生物群失调密切相关的显著代谢紊乱。他们还表现出胆汁酸(BA)谱紊乱,糖脱氧胆酸(GDCA)缺失被认为是OP和健康对照之间最有效的鉴别因子。粪便微生物群移植(FMT)再现了代谢功能障碍和BA池重塑,其介导的BA合成基因Cyp8a1、Cyp7a1和Cyp7b1的肝脏表达失调。值得注意的是,FMT-OP小鼠也表现出在OP受试者中观察到的GDCA水平降低。在肥胖小鼠中补充GDCA可显著改善体重、肝脂肪变性和代谢功能障碍。从机制上看,GDCA通过激活TGR5信号通路,增强褐色脂肪组织(BAT)产热,刺激回肠胰高血糖素样肽-1 (GLP-1)分泌,从而发挥抗肥胖作用,改善肥胖及相关代谢失调。因此,这些发现表明,肠道微生物群驱动的BA信号失调,特别是由于GDCA减少而导致的TGR5激活受损,是OP个体糖脂代谢功能障碍的基础。
{"title":"Gut microbiota drives the metabolic dysregulation in obesity-prone individuals by impairing GDCA-mediated activation of brown adipose thermogenesis and ileal GLP-1 secretion","authors":"Han Ma ,&nbsp;Yuqi Wu ,&nbsp;Delong Li ,&nbsp;Haowen Sun ,&nbsp;Yuan Xie ,&nbsp;Shichun Zhao ,&nbsp;Wenqian Guo ,&nbsp;Meng Wang ,&nbsp;Renyun Cui ,&nbsp;Yanrong Huang ,&nbsp;Xiankang Zhang ,&nbsp;Jin-Yi Wan ,&nbsp;Haiqiang Yao ,&nbsp;Chun-Su Yuan","doi":"10.1016/j.apsb.2025.12.006","DOIUrl":"10.1016/j.apsb.2025.12.006","url":null,"abstract":"<div><div>Obesity-prone (OP) individuals exhibit an intrinsic predisposition to obesity and associated metabolic disorders, and early intervention in this population holds significant clinical value; however, the underlying mechanisms driving this susceptibility remain largely obscure. This study enrolled 46 OP subjects without diagnosed metabolic diseases and 35 healthy controls. Our findings revealed that, despite not reaching obesity diagnoses, OP subjects exhibited significant metabolic disturbances strongly associated with gut microbiota dysbiosis. They also displayed disturbed bile acid (BA) profiles, with depleted glycodeoxycholic acid (GDCA) identified as the most potent discriminator between the OP and healthy controls. Fecal microbiota transplantation (FMT) recapitulated metabolic dysfunction and BA pool remodeling, mediated by dysregulated hepatic expression of BA synthesis genes of <em>Cyp8a1</em>, <em>Cyp7a1</em>, and <em>Cyp7b1</em>. Notably, FMT-OP mice also phenocopied the diminished GDCA levels observed in OP subjects. GDCA supplementation in obese mice markedly improved body weight, hepatic steatosis, and metabolic dysfunction. Mechanistically, GDCA exerted anti-obesity effects by activating the TGR5 signaling, which enhanced brown adipose tissue (BAT) thermogenesis and stimulated ileal glucagon-like peptide-1 (GLP-1) secretion, thereby ameliorating obesity and associated metabolic dysregulation. Thus, these findings indicate that gut microbiota-driven dysregulation of BA signaling, particularly impaired TGR5 activation due to diminished GDCA, underlies glycolipid metabolic dysfunction in OP individuals.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 836-853"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma 从计算模拟中获得的皮肤穿透肽改善透皮吸收,促进黑色素瘤的局部治疗。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-22 DOI: 10.1016/j.apsb.2025.12.026
Sanjiang Du , Hanlin Wang , Feiyang Geng , Zongxu Zhang , Chenghao Liu , Weiyue Lu , Gang Wei
Transdermal drug delivery relies heavily on the skin permeability of therapeutic agents. In order to develop a peptide-based delivery strategy for promoting transdermal absorption, the key physicochemical factors influencing skin permeability are first identified through cell-penetrating peptides (CPPs) screening and computational simulation. Penetratin exhibits the most outstanding permeability and safety among CPPs from various origins, and positive surface patch area emerges as the key property correlated with skin permeability of the peptides. Based on these findings, a precise model to predict skin permeability of the peptides is established, leading to the computational redesign of penetratin’s amino acid sequence. The transdermal delivery efficiency of optimized penetratin derivative (589WP) is significantly improved in vitro compared with wild-type penetratin and visualized through in vivo imaging. Furthermore, the anti-metabolic drug floxuridine (FUdR) is covalently conjugated with 589WP via ester linkage, leading to accelerated FUdR release due to esterase degradation. Subsequently, this conjugate is formulated into an anhydrous gel, which significantly inhibits melanoma growth with topical application, outperforming a higher dose of free FUdR without observed skin irritancy or toxicity. The peptide prediction and design approaches established herein hold great potential for advancing transdermal drug delivery.
经皮给药在很大程度上依赖于治疗剂的皮肤渗透性。为了开发一种基于多肽的促进透皮吸收的递送策略,首先通过细胞穿透肽(CPPs)筛选和计算模拟确定了影响皮肤渗透性的关键理化因素。在不同来源的CPPs中,渗透素表现出最突出的渗透性和安全性,正表面斑块面积是与皮肤渗透性相关的关键特性。基于这些发现,建立了一个精确的模型来预测肽的皮肤渗透性,从而导致穿透素氨基酸序列的计算重新设计。与野生型穿透素相比,优化后的穿透素衍生物(589WP)的体外透皮递送效率显著提高,并通过体内显像可见。此外,抗代谢药物氟尿定(FUdR)通过酯键与589WP共价偶联,导致酯酶降解加速FUdR的释放。随后,将该缀合物配制成无水凝胶,局部应用可显著抑制黑色素瘤生长,优于高剂量的游离FUdR,且未观察到皮肤刺激或毒性。本文建立的多肽预测和设计方法在推进经皮给药方面具有很大的潜力。
{"title":"Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma","authors":"Sanjiang Du ,&nbsp;Hanlin Wang ,&nbsp;Feiyang Geng ,&nbsp;Zongxu Zhang ,&nbsp;Chenghao Liu ,&nbsp;Weiyue Lu ,&nbsp;Gang Wei","doi":"10.1016/j.apsb.2025.12.026","DOIUrl":"10.1016/j.apsb.2025.12.026","url":null,"abstract":"<div><div>Transdermal drug delivery relies heavily on the skin permeability of therapeutic agents. In order to develop a peptide-based delivery strategy for promoting transdermal absorption, the key physicochemical factors influencing skin permeability are first identified through cell-penetrating peptides (CPPs) screening and computational simulation. Penetratin exhibits the most outstanding permeability and safety among CPPs from various origins, and positive surface patch area emerges as the key property correlated with skin permeability of the peptides. Based on these findings, a precise model to predict skin permeability of the peptides is established, leading to the computational redesign of penetratin’s amino acid sequence. The transdermal delivery efficiency of optimized penetratin derivative (589WP) is significantly improved <em>in vitro</em> compared with wild-type penetratin and visualized through <em>in vivo</em> imaging. Furthermore, the anti-metabolic drug floxuridine (FUdR) is covalently conjugated with 589WP <em>via</em> ester linkage, leading to accelerated FUdR release due to esterase degradation. Subsequently, this conjugate is formulated into an anhydrous gel, which significantly inhibits melanoma growth with topical application, outperforming a higher dose of free FUdR without observed skin irritancy or toxicity. The peptide prediction and design approaches established herein hold great potential for advancing transdermal drug delivery.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1140-1154"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Pharmaceutica Sinica. B
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1